| Literature DB >> 31341498 |
Linchang Liu1,2, Zhiwei Yin1, Jiwei Ma1, Shuwei Duan1, Xiangmei Chen1.
Abstract
OBJECTIVE: This study investigated the association between body constitution (BC) and the prognosis of IgA nephropathy.Entities:
Year: 2019 PMID: 31341498 PMCID: PMC6612381 DOI: 10.1155/2019/6289478
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Distribution of BC in IgA nephropathy group and the control group.
| Characteristics | IgA nephropathy group (n=203) | the control group (n=64) |
|
|---|---|---|---|
| Age (years) | 40.1±11.6 | 42.4±18.4 | 0.352 |
| Male (n (%)) | 111 (54.7) | 34 (53.1) | 0.828 |
| Gentleness BC (n (%)) | 32(15.8) | 18(28.1) | 0.027 |
| Yang-deficiency BC (n (%)) | 97(47.8) | 23(35.9) | 0.097 |
| Yin-deficiency BC (n (%)) | 80(39.4) | 23(35.9) | 0.619 |
| Qi-deficiency BC (n (%)) | 114(56.2) | 24(37.5) | 0.009 |
| Phlegm-dampness BC (n (%)) | 90(44.3) | 19(29.7) | 0.038 |
| Dampness-heat BC (n (%)) | 93(45.8) | 16(25.0) | 0.003 |
| Blood-stasis BC (n (%)) | 64(31.5) | 12(18.8) | 0.048 |
| Qi-depression BC (n (%)) | 41(20.2) | 10(15.6) | 0.417 |
| Special diathesis BC (n (%)) | 80(39.4) | 15(23.4) | 0.020 |
| No BC (n (%)) | 4(2.0) | 2(3.1) | 0.587 |
Number of BC types in IgA nephropathy group and the control group (n (%)).
| Number of BC types | IgA nephropathy group (n=203) | the control group (n=64) |
|---|---|---|
| 0 | 4(2.0) | 2(3.1) |
| 1 | 62(30.5) | 26(40.6) |
| 2 | 22(10.8) | 7(10.9) |
| 3 | 27(13.3) | 14(21.9) |
| 4 | 19(9.4) | 7(10.9) |
| 5 | 25(12.3) | 2(3.1) |
| 6 | 15(7.4) | 2(3.1) |
| 7 | 19(9.4) | 4(6.3) |
| 8 | 10(5.0) | 0(0) |
Clinical characteristics at biopsy and follow-up for patients with Yang-deficiency BC and non-Yang-deficiency BC.
| Characteristics | Yang-deficiency BC (n=97) | Non-Yang-deficiency BC (n=106) |
|
|---|---|---|---|
| Age (years) | 41.0±10.9 | 39.2±12.1 | 0.271 |
| Male (n (%)) | 44 (45.4) | 67 (63.2) | 0.011 |
| BMI (kg/m2) | 24.2±4.0 | 24.7±3.4 | 0.386 |
| Smoking (n (%)) | 20(20.6) | 27(25.5) | 0.413 |
| Alcohol drinking (n (%)) | 18(18.6) | 24(22.6) | 0.473 |
| Less exercise (n (%)) | 26(26.8) | 26(24.5) | 0.711 |
| MAP(mmHg) | 99.1±13.8 | 97.3±12.6 | 0.352 |
| Urinary protein (g/d) | 1.78±1.80 | 1.58±1.32 | 0.398 |
| Serum albumin (g/L) | 37.4±6.0 | 39.6±5.5 | 0.009 |
| eGFR (ml/min) | 80.2±29.0 | 80.3±28.7 | 0.985 |
| Serum uric acid ( | 374.2±97.6 | 389.7±103.7 | 0.275 |
| CKD stage (n (%)) | 0.989 | ||
| stage 1 | 43(44.3) | 45(42.5) | |
| stage 2 | 26(26.8) | 29(27.4) | |
| stage 3 | 25(25.8) | 28(26.4) | |
| stage 4 | 3(3.1) | 4(3.8) | |
| Treatment | 45(46.4) | 58(54.7) | 0.236 |
| Follow-up (months) | 64.6±17.8 | 63.4±14.5 | 0.600 |
| Endpoint event (n (%)) | 23(23.7) | 9(8.5) | 0.003 |
∗Corticosteroid and/or immunosuppressant treatments; BMI: body mass index; MAP: mean arterial pressure; eGFR: estimated glomerular filtration rate; CKD: chronic kidney disease; endpoint event: 50% decline in eGFR or end-stage renal disease.
Clinical characteristics at biopsy and follow-up for patients with blood-stasis BC and non-blood-stasis BC.
| Characteristics | Blood-stasis BC (n=64) | Non- Blood-stasis BC (n=139) |
|
|---|---|---|---|
| Age (years) | 39.6±10.4 | 40.3±12.1 | 0.689 |
| Male (n (%)) | 19 (29.7) | 92 (66.2) | 0.001 |
| BMI (kg/m2) | 24.5±4.3 | 24.4±3.4 | 0.955 |
| Smoking (n (%)) | 12(18.8) | 35(25.2) | 0.313 |
| Alcohol drinking (n (%)) | 14(21.9) | 28(20.1) | 0.777 |
| Less exercise (n (%)) | 14(21.9) | 38(27.3) | 0.407 |
| MAP(mmHg) | 98.5±13.1 | 98.0±13.3 | 0.819 |
| Urinary protein (g/d) | 1.92±1.70 | 1.56±1.49 | 0.144 |
| Serum albumin (g/L) | 37.0±5.8 | 39.4±5.7 | 0.008 |
| eGFR (ml/min) | 77.1±30.0 | 81.7±28.2 | 0.299 |
| Serum uric acid ( | 410.5±118.7 | 369.3±89.0 | 0.007 |
| CKD stage (n (%)) | 0.739 | ||
| stage 1 | 25(39.1) | 63(45.3) | |
| stage 2 | 17(26.6) | 38(27.3) | |
| stage 3 | 19(29.7) | 34(24.5) | |
| stage 4 | 3(4.7) | 4(2.9) | |
| Treatment | 31(48.4) | 72(51.8) | 0.656 |
| Follow-up (months) | 64.8±17.3 | 63.6±15.6 | 0.624 |
| Endpoint event (n (%)) | 18(28.1) | 14(10.1) | 0.001 |
∗Corticosteroid and/or immunosuppressant treatments; BMI: body mass index; MAP: mean arterial pressure; eGFR: estimated glomerular filtration rate; CKD: chronic kidney disease; endpoint event: 50% decline in eGFR or end-stage renal disease.
Factors influencing renal survival from endpoint event by univariate and multivariate Cox regression.
| Characteristics | Univariate | Multivariate | ||
|---|---|---|---|---|
| HR(95%CI) |
| HR(95%CI) |
| |
| Hypertension | 6.5(2.9-14.5) | <0.001 | 3.5(1.4-8.7) | 0.009 |
| Renal impairment | 10.6(4.4-25.8) | <0.001 | 5.8(2.2-15.4) | <0.001 |
| Yang-deficiency BC | 2.3 (1.1-5.1) | 0.033 | 2.3(1.0-5.2) | 0.041 |
| Blood-stasis BC | 2.3 (1.2-4.8) | 0.019 | 2.5(1.2-5.2) | 0.017 |
| Proteinuria of more than 1g/d | 2.4 (1.0-5.4) | 0.037 | NS | |
| Hypoproteinemia | 2.8(1.3-5.8) | 0.007 | NS | |
| Hyperuricemia | 7.3(3.3-15.8) | <0.001 | NS | |
Hypertension: blood pressure >140/90 mmHg or requirement for antihypertensive therapy; renal impairment: eGFR<60 mL/min. Hypoproteinemia: serum albumin <35 g/L; hyperuricemia: serum uric acid >420μmol/L; NS: not significant.